Pharmaceutical

Emergent scores US medical countermeasure contracts worth over $250m

Emergent will supply vaccines for anthrax and smallpox, VIV for treating smallpox vaccine complications, and a botulism antitoxin.

Jul 4, 2024 - 04:00
Emergent scores US medical countermeasure contracts worth over $250m
Emergent will supply vaccines for anthrax and smallpox, VIV for treating smallpox vaccine complications, and a botulism antitoxin.
Read the original article

Tags:

Previous Article

Biogen completes $1.15bn HI-Bio acquisition to expand immunology presence

Next Article

EMA approves Sanofi’s Dupixent for COPD treatment in adults

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: Cord blood banking sounds like a great idea — until you realize what it costs babies

Opinion: Cord blood banking sounds like a great idea — ...

Jan 16, 2024

STAT+: Sanofi CEO defends company’s move to abandon profit guidance and boost research

STAT+: Sanofi CEO defends company’s move to abandon pro...

Nov 9, 2023

STAT+: Federal Medicaid officials cajole states to auto-enroll beneficiaries as huge coverage losses loom

STAT+: Federal Medicaid officials cajole states to auto...

Mar 19, 2023